```html

Wegovy (Semaglutide) Side Effects – A Comprehensive Medical Guide

Overview

Wegovy® (generic name: semaglutide) is a once‑weekly injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist approved by the U.S. Food and Drug Administration (FDA) in June 2021 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight‑related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Semaglutide works by mimicking the body's natural GLP‑1 hormone, which:

• Enhances insulin secretion after meals
• Slows gastric emptying
• Reduces appetite and food intake

Because it influences gastrointestinal (GI) function and glucose metabolism, a variety of side effects can occur. Understanding these effects helps patients and clinicians weigh benefits against risks.

Who it affects: As of 2024, Wegovy is prescribed to an estimated over 1 million adults in the United States. Most users are adults aged 18–65, though the FDA now also permits use in adolescents ≥ 12 years (with a BMI ≥ 30 kg/m²) under specialist supervision.

Symptoms

Side effects are usually dose‑related and appear within the first few weeks of therapy. Below is a complete, alphabetically organized list with brief descriptions.

Common (≥ 10% of users)

• Nausea – A queasy sensation that may lead to vomiting; often mild and improves over time.
• Diarrhea – Loose, watery stools; can be mild to moderate.
• Constipation – Hard, infrequent stools; may coexist with other GI symptoms.
• Abdominal pain / discomfort – Cramping or fullness.
• Decreased appetite – Desired therapeutic effect but can be excessive, leading to inadequate nutrient intake.
• Vomiting – Typically occurs early in treatment; may be triggered by rapid dose escalation.
• Headache – Mild to moderate, often resolves without medication.
• Fatigue – General tiredness, especially in the first few weeks.

Less Common (1‑10% of users)

• Indigestion (dyspepsia) – Burning or gnawing sensation in the upper abdomen.
• Flatulence – Excess gas or bloating.
• Acid reflux / heartburn.
• Dizziness – Often related to dehydration from GI losses.
• Hypoglycemia – Low blood sugar, mainly in patients with type 2 diabetes on insulin or sulfonylureas.
• Injection site reactions – Redness, bruising, or mild pain at the thigh or abdomen.
• Elevated heart rate (tachycardia) – Small increase (≈2–3 bpm) observed in some trials.

Rare (< 1% of users) but serious

• Pancreatitis – Sudden, severe upper‑abdominal pain radiating to the back, often with nausea and vomiting.
• Gallbladder disease – Cholelithiasis or cholecystitis; risk may increase due to rapid weight loss.
• Severe allergic reactions – Anaphylaxis, angioedema, or urticaria.
• Kidney injury – Acute renal failure secondary to dehydration.
• Thyroid C‑cell tumors – Observed in rodent studies; human relevance uncertain, but contraindicated in patients with a personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

Causes and Risk Factors

Wegovy’s side effects stem from its pharmacologic actions and the patient’s baseline health status.

Mechanistic Basis

• GLP‑1–mediated slowing of gastric emptying – Leads to early satiety, nausea, and sometimes constipation.
• Central appetite suppression – Can overshoot, causing very low caloric intake.
• Glucose‑dependent insulin secretion – May precipitate hypoglycemia when combined with other glucose‑lowering agents.

Risk Factors for More Severe or Persistent Side Effects

• Pre‑existing GI disorders (e.g., IBS, chronic constipation)
• History of pancreatitis or gallbladder disease
• Concurrent use of medications that slow gut motility (opioids, anticholinergics)
• Rapid dose escalation or skipping the recommended titration schedule
• Dehydration or insufficient fluid intake
• Renal impairment (eGFR < 60 mL/min/1.73 m²)
• Pregnancy, breastfeeding, or planning a pregnancy (safety not established)

Diagnosis

Diagnosing a side effect is primarily clinical—recognizing the temporal relationship between Wegovy initiation and symptom onset.

Initial Assessment

1. Detailed history: dosage, titration schedule, other medications, recent dietary changes.
2. Physical examination focusing on abdomen, hydration status, and injection sites.

Laboratory & Imaging Tests (when indicated)

• Serum amylase/lipase – Elevated levels suggest pancreatitis.
• Liver function tests (ALT, AST, ALP, bilirubin) – To rule out biliary obstruction.
• Renal panel (creatinine, BUN, electrolytes) – Detect dehydration‑related kidney injury.
• Ultrasound of the abdomen – Evaluate gallbladder for stones or inflammation.
• Thyroid ultrasound & calcitonin – Only in patients with a strong suspicion of thyroid neoplasia.

Monitoring Schedule Recommended by Guidelines

Time Point	What to Monitor
Baseline	Weight, BMI, HbA1c (if diabetic), renal function, pancreatitis history.
Weeks 4‑8	GI symptoms, hydration status, any signs of pancreatitis.
Every 3‑6 months	Weight loss progress, metabolic labs, renal function.

Treatment Options

Management aims to relieve symptoms while maintaining the therapeutic weight‑loss benefit.

Pharmacologic Interventions

• Antiemetics – Ondansetron 4–8 mg PO/IV PRN for nausea.
• Antidiarrheals – Loperamide 2 mg after the first loose stool, not exceeding 8 mg/day.
• Laxatives – Polyethylene glycol 17 g PO once daily for constipation, if dietary measures fail.
• Proton‑pump inhibitors (PPIs) – For persistent heartburn.
• Insulin or sulfonylurea dose reduction – To prevent hypoglycemia in diabetic patients.

Non‑pharmacologic Strategies

• Slow titration – Follow the 4‑step schedule (0.25 mg → 0.5 mg → 1 mg → 2.4 mg) and do not skip steps.
• Hydration – Aim for ≥2 L of water daily; use oral rehydration solutions if vomiting is severe.
• Dietary adjustments – Small, frequent meals; low‑fat, high‑protein foods; avoid large meals that exacerbate nausea.
• Physical activity – Light walking can aid GI motility.
• Injection technique education – Rotate sites, inject subcutaneously, and store pen per manufacturer instructions.

When to Adjust or Discontinue Wegovy

Consider dose reduction or temporary interruption if:

• Persistent grade 3 nausea/vomiting (≥ 10 episodes in 24 h) despite antiemetics.
• Signs of pancreatitis, gallbladder disease, or allergic reaction.
• Renal function drops >30% from baseline.

Living with Wegovy (Semaglutide) Side Effects

Successful long‑term use relies on practical daily habits.

Nutrition Tips

• Start the day with a protein‑rich breakfast (Greek yogurt, eggs, or a protein shake).
• Incorporate soluble fiber (oats, chia, psyllium) to reduce constipation.
• Limit high‑fat, fried, and spicy foods that can worsen nausea.
• Consume a balanced electrolyte drink (e.g., 250 ml of a solution containing 150 mg sodium and 60 mg potassium) if you experience diarrhea.

Hydration & Fluid Management

• Set a reminder to drink a glass of water every hour.
• Carry a reusable bottle and track intake with a smartphone app.
• If vomiting occurs, sip clear fluids (broth, diluted juice) every 15 minutes.

Physical Activity

• Engage in low‑impact exercise (walking, stationary cycling) for 150 minutes/week.
• Avoid intense workouts during periods of severe GI upset.

Stress & Mental Health

• Practice relaxation techniques (deep breathing, progressive muscle relaxation) to reduce nausea‑related anxiety.
• Join a support group—online forums such as r/semaglutide provide peer experiences.
• Speak with a mental‑health professional if mood changes or disordered eating patterns develop.

Follow‑up Schedule

Schedule visits with your prescribing clinician at 4 weeks, 12 weeks, and then every 3‑6 months. Bring a side‑effect diary to each appointment.

Prevention

While side effects cannot be eliminated entirely, their incidence can be reduced.

1. Adhere to the titration schedule – Skipping steps markedly increases GI intolerance.
2. Stay hydrated – Adequate fluids blunt constipation and kidney stress.
3. Eat mindfully – Small meals, chew thoroughly, and avoid lying down immediately after eating.
4. Review concomitant meds – Discuss any drugs that affect gut motility with your provider.
5. Screen for contraindications – Prior pancreatitis, gallbladder disease, or a personal/family history of MTC should be identified before prescribing.

Complications

If side effects are ignored or inadequately treated, they can evolve into serious health issues.

• Severe dehydration → electrolyte imbalances, acute kidney injury.
• Acute pancreatitis → may require hospitalization, can be life‑threatening.
• Gallstone formation – Rapid weight loss speeds cholesterol supersaturation in bile.
• Nutrient deficiencies – Prolonged poor intake can lead to iron, vitamin B12, or calcium deficits.
• Psychological distress – Persistent nausea or vomiting may trigger anxiety, depression, or disordered eating.

When to Seek Emergency Care

Sources

• Mayo Clinic. “Semaglutide (Wegovy) side effects.” https://www.mayoclinic.org
• CDC. “Obesity and weight‑management clinical care.” https://www.cdc.gov
• NIH. “GLP‑1 receptor agonists for obesity.” https://www.niddk.nih.gov
• American Diabetes Association. “Pharmacologic Approaches to Obesity.” Diabetes Care 2023;46(Suppl 1):S101‑S110.
• FDA. “Wegovy (semaglutide) prescribing information.” https://www.fda.gov
• Cleveland Clinic. “Managing side effects of GLP‑1 drugs.” https://my.clevelandclinic.org

```